Sensitivity analyses of linezolid against clinical gram-positive cocci isolates in vitro

Abstract

Abstract: AIM: To compare the antibacterial activity of linezolid with vancomycin and other antibacterials against clinical gram-positive cocci isolates in vitro.METHODS: The antibacterial activity of linezolid and other antibacterials were determined according to the disk diffusion guidelines of NCCLS (CLSI) 2007 in vitro.RESULTS: The incidence of methicillin^- resistant Staphylococcus aureus (MRSA) isolated in our hospital was 79.1%, linezolid showed great susceptibility as well as vancomycin and teicoplanin.The incidence of methicillin-resistant coagulase negative Staphylococcus (MRCNS, 88.9%) was higher than that of MRSA, the antibacterial activity of linezolid was comparable with that of vancomycin and teicoplanin, and the sensitivity was 100%.The activity of linezolid against enterococcus faecalis is similar to that of vancomycin and teicoplanin, the activity of linezolid against enterococcus faecium is prior to that of vancomycin and teicoplanin (100%, 80.4%, 78.1%).Linezolid also showed great activity against penicillin resistant streptococcus pneumonia (PRSP).CONCLUSION: The antibacterial activity of linezolid was comparable with that of vancomycin and teicoplanin against MRSA, MRCNS, PRSP and enterococcus faecalis, and the sensitivity were all 100%.The antibacterial activity was better than those of the two drugs against enterococcus faecium in vitro.Linezolid could be a promising therapeutic option to treat infections caused by multi-resistant gram-positive cocci.

Key words: linezolid, vancomycin, gram-positivecocci, multidrugresistance, sensitivity, invitro

CLC Number:

R965.2

XIAO Xiu-mei, LIU Zheng-ying, ZHANG Xiao-wei, ZHANG Jie. Sensitivity analyses of linezolid against clinical gram-positive cocci isolates in vitro[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(9): 1048-1052.

References

[1] Rice LB.Antimicrobial resistance in gram-positive bacteria [J].Am J Infect Control, 2006, 34(5 Suppl 1):S11-9:discussion S64-73.
[2] Burleson BS, Ritchie DJ, Micek ST, et al. Enterococcus faecalis resistant to linezolid:case series and review of the literature [J].Pharmacotherapy, 2004, 24 (9):1225-1231.
[3] Moellering RC.Linezolid:the first oxazolidinone antimicrobial [J].Ann Intern Med, 2003, 138(2):135-142.
[4] French G.Linezolid [J].Int J Clin Pract, 2001, 55(1): 59-63.
[5] Schwalbe RS, Stapleton JT, Gilligan PH.Emergence of vancomycin resistance in coagulase-negative staphylococci [J].N Engl J Med, 1987, 316(15):927-931.
[6] Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility [J].J Antimicrob Chemother, 1997, 40(1):135-136.
[7] Credito K, Lin G, Appelbaum PC.Antistaphylococcal activity of DX-619 alone and in combination with vancomycin, teicoplanin, and linezolid assessed by time-kill synergy testing [J].Antimicrob Agents Chemother, 2007, 51 (4):1508-1511.
[8] Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections [J].Antimicrob Agents Chemother, 2005, 49 (6):2260-2266.
[9] Gee T, Ellis R, Marshall G, et al. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses [J].Antimicrob Agents Chemother, 2001, 45(6):1843-1846.
[10] Rybak MJ, Cappelletty DM, Moldovan T, et al. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomy cin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium [J].Antimicrob Agents Chemother, 1998, 42(3):721-724.
[11] Noskin GA, Siddiqui F, Stosor V, et al. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomy cin-resistant enterococci [J].Antimicrob Agents Chemother, 1999, 43(8):2059-2062.
[12] Zurenko GE, Yagi BH, Schaadt RD, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents [J].Antimicrob Agents Chemother, 1996, 40(4):839-845.
[13] Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus [J]. Lancet, 2001, 358(9277):207-208.
[14] Mutnick AH, Enne V, Jones RN.Linezolid resistance since 2001:SENTRY Antimicrobial Surveillance Program [J].Ann Pharmacother, 2003, 37(6):769-774.

[1]	WU Lili, LIANG Zhi, HUANG Siyong, WANG Yan. Effect of augmented renal clearance (ARC) on the pharmacokinetics, efficacy, and safety of vancomycin in patients with infective endocarditis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1139-1145.
[2]	LIN Liangmo, FU Xiangjun, ZHONG Lili, WANG Hefang, WU Qiongshi, XIAO Jian. Establishment of population pharmacokinetics model of vancomycin in patients with Neutropenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1014-1022.
[3]	JIAO Zhigang, FAN Ru, XU Biyun, CHEN Sizhen, ZANG Yiteng, WANG shiyuan, CHEN Bingwei . Multiple imputation of missing data in clinical longitudinal studies and its sensitivity analyses [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1037-1041.
[4]	FU Xiangjun, HUANG Li, GUO Li, LIN Liangmo. Application of AUC/MIC as the therapeutic drug monitoring target of vancomycin in patients with severe infections of multi drug resistant gram positive bacteria [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 775-781.
[5]	LU Qiong, ZHU Haihong, QI Tingting, LI Guohua, TENG Xinqi, QU Qiang, QU Jian. OCTN2 gene polymorphisms affect the chemotherapeutic sensitivity of oxaliplatin in colorectal cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 401-407.
[6]	GUO Xianzhong, LIN Rongfang, LIN Weiwei. Development of software for individualizing dosage regimens of vancomycin based on population pharmacokinetics models [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 30-39.
[7]	LIN Zhong, XIE Qunli, DAI Shuping, CHEN Jing, LIN Feiyang, ZHU Yanwu, YU Guoliang, ZHANG Yuanhuai, CUI Ke. Population pharmacokinetics of Linezolid in Chinese adult infection patients#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 992-999.
[8]	. Research progress of linezolid-induced lactic acidosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(12): 1408-1413.
[9]	ZHENG Zhongqiu, XIE Bojian, CUI Binbin, KE Yichen, LIN Yi. miR-106 b expression in breast cancer tissues and mechanism of enhancing cisplatin sensitivity in breast cancer cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 541-545.
[10]	DONG Wei, TANG Xilan, ZHAO Guowei, JIANG Qieying, LIAO Zhenggen, LIANG Xinli. Effects of coumarins from Angelica dahurica on chemotherapeutic sensitivity of human breast cancer cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(2): 140-146.
[11]	ZHU Min, ZHANG Cuifeng, GUO Yiyun, ZHU Ziming. Population pharmacokinetics of vancomycin in elderly infectious patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(2): 158-163.
[12]	WANG Jing, ZHOU Haibin, GU Weigang, WANG Xia, YANG Jianfeng. Effect of ketotifen on gastrointestinal symptoms, visceral sensitivity and intestinal mast cells in patients with irritable bowel syndrome with diarrheal [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 63-70.
[13]	WANG Jin, YANG Yi, GUAN Qiaobin, CHEN Qixu, GUO Li, HAN Chenyang. YAP gene silencing to improve the drug sensitivity of imatinib resistant myeloid leukemia cells K562 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(9): 1008-1014.
[14]	FANG Weiyang, LI Yue, SHENG Lei, CUI Zhenzhen, ZHONG Fei, TONG Zhuting. Effects of bufalin on radiosensitivity of esophageal cancer Kyse150 cell line [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 728-733.
[15]	CHEN Yaoyao，SHI Daohua，LIU Guanghua，NIU Peiguang，LIU Baichen. Effects of OCT2 and MDR1 gene polymorphisms on vancomycin concentration and clinical efficacy in infants [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 154-158.